Geovax Labs Inc (GOVX) 0.2400 $GOVX
GeoVax's Chief Scientific Officer to Present at HIV Vaccine Conference
ACCESSWIRE - Thu Sep 25, 8:17AM CDT
ATLANTA, GA / ACCESSWIRE / September 25, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., will participate in a panel discussion on HIV vaccine clinical trials on October 7, 2014 at the 2014 Cent Gardes HIV Vaccine Conference in Veyrier du Lac, France. In the introduction to the discussion, Dr. Robinson will provide an update on GeoVax's HIV vaccine trials, "Clade B VLP expressing DNA/MVA Vaccine."
GeoVax's Chief Scientific Officer Featured as Lecturer at American Society for Microbiology Conference
eTeligis - Thu Sep 04, 9:50AM CDT
ATLANTA, GA, United States, via ETELIGIS INC., 09/04/2014 - - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., presented a virtual lecture entitled "Working Towards an HIV Vaccine," on August 29, 2014 at the African Center for Integrated Laboratory Training in Sandringham, South Africa, sponsored by the American Society for Microbiology.
GeoVax to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
ACCESSWIRE - Wed Sep 03, 8:17AM CDT
ATLANTA, GA / ACCESSWIRE / September 3, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, today announced that it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City. Robert McNally, Ph.D., President and CEO of GeoVax, will deliver the Company presentation to conference attendees on Tuesday, September 9 at 3:20 pm in the Adams Salon at the New York Palace Hotel. Dr. McNally will be joined at the conference by Mark Reynolds, GeoVax's CFO.
GeoVax Reports 2014 Second Quarter Financial Results and Provides Corporate Update
ACCESSWIRE - Thu Aug 07, 8:18AM CDT
ATLANTA, GA / ACCESSWIRE / August 7, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the three and six months ended June 30, 2014 and provided a clinical development update.
GeoVax Announces Clinical Development License Agreement with Valneva SE
ACCESSWIRE - Wed Aug 06, 7:15AM CDT
Use of Valneva's EB66(R) Cell Line to Aid in Development of Commercial-Scale Manufacturing Process for GeoVax's HIV/AIDS Vaccine
VALNEVA enters into clinical development license agreement with GeoVax
M2 - Wed Aug 06, 5:32AM CDT
Biotechnology company Valneva SE announced on Wednesday that it has executed a clinical development license agreement to develop MVA-based vaccines in its EB66 vaccine production cell line.
GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health
ACCESSWIRE - Wed Jul 16, 8:17AM CDT
Atlanta, GA / ACCESSWIRE / July 16, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Small Business Innovative Research (SBIR) grant entitled "Enhancing Protective Antibody Responses for a GM-CSF Adjuvanted HIV Vaccine." The grant award of approximately $290,000 is for the second year of a two-year project period.
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
GeoVax Announces Publication of Repeat Challenge Preclinical Trial in the Journal of Virology
Marketwire - Wed Mar 19, 10:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today the publication of the results of a study in which non-human primates vaccinated with simian prototypes of its HIV vaccine resisted up to 41 rectal exposures to simian immunodeficiency virus (SIV). The article, titled "Local Control of Repeated Rectal Challenges in DNA/MVA Vaccinated Macaques Protected Against a 1st Series of SIV Challenges" was published on-line in the Journal of Virology. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24574408. The print version will be available in May.
GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update
Marketwire - Wed Mar 05, 7:15AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2013 and provided the following corporate update.
GeoVax Presents at the Phacilitate Vaccine Forum 2014
Marketwire - Tue Jan 28, 12:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today that its Chief Scientific Officer, Dr. Harriet Robinson, presented information on the selection of antigens and antigen combinations for the elicitation of protective antibody responses for HIV at the Phacilitate Vaccine Forum 2014 on January 27, 2014 in Washington, DC.
GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases
Marketwire - Thu Jan 23, 9:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today the publication of the results of Phase 2a clinical testing of its JS7/MVA62B AIDS vaccine, GOVX-B11. The article, titled "Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles" was published on-line in The Journal of Infectious Diseases. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24403557.
GeoVax's Chief Scientific Officer to Present at HIV Vaccine Conference
ACCESSWIRE - Thu Sep 25, 8:17AM CDT
ATLANTA, GA / ACCESSWIRE / September 25, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., will participate in a panel discussion on HIV vaccine clinical trials on October 7, 2014 at the 2014 Cent Gardes HIV Vaccine Conference in Veyrier du Lac, France. In the introduction to the discussion, Dr. Robinson will provide an update on GeoVax's HIV vaccine trials, "Clade B VLP expressing DNA/MVA Vaccine."
GeoVax's Chief Scientific Officer Featured as Lecturer at American Society for Microbiology Conference
eTeligis - Thu Sep 04, 9:50AM CDT
ATLANTA, GA, United States, via ETELIGIS INC., 09/04/2014 - - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., presented a virtual lecture entitled "Working Towards an HIV Vaccine," on August 29, 2014 at the African Center for Integrated Laboratory Training in Sandringham, South Africa, sponsored by the American Society for Microbiology.
GeoVax to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
ACCESSWIRE - Wed Sep 03, 8:17AM CDT
ATLANTA, GA / ACCESSWIRE / September 3, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, today announced that it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City. Robert McNally, Ph.D., President and CEO of GeoVax, will deliver the Company presentation to conference attendees on Tuesday, September 9 at 3:20 pm in the Adams Salon at the New York Palace Hotel. Dr. McNally will be joined at the conference by Mark Reynolds, GeoVax's CFO.
GeoVax Reports 2014 Second Quarter Financial Results and Provides Corporate Update
ACCESSWIRE - Thu Aug 07, 8:18AM CDT
ATLANTA, GA / ACCESSWIRE / August 7, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the three and six months ended June 30, 2014 and provided a clinical development update.
GeoVax Announces Clinical Development License Agreement with Valneva SE
ACCESSWIRE - Wed Aug 06, 7:15AM CDT
Use of Valneva's EB66(R) Cell Line to Aid in Development of Commercial-Scale Manufacturing Process for GeoVax's HIV/AIDS Vaccine
VALNEVA enters into clinical development license agreement with GeoVax
M2 - Wed Aug 06, 5:32AM CDT
Biotechnology company Valneva SE announced on Wednesday that it has executed a clinical development license agreement to develop MVA-based vaccines in its EB66 vaccine production cell line.
GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health
ACCESSWIRE - Wed Jul 16, 8:17AM CDT
Atlanta, GA / ACCESSWIRE / July 16, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Small Business Innovative Research (SBIR) grant entitled "Enhancing Protective Antibody Responses for a GM-CSF Adjuvanted HIV Vaccine." The grant award of approximately $290,000 is for the second year of a two-year project period.
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
GeoVax Announces Publication of Repeat Challenge Preclinical Trial in the Journal of Virology
Marketwire - Wed Mar 19, 10:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today the publication of the results of a study in which non-human primates vaccinated with simian prototypes of its HIV vaccine resisted up to 41 rectal exposures to simian immunodeficiency virus (SIV). The article, titled "Local Control of Repeated Rectal Challenges in DNA/MVA Vaccinated Macaques Protected Against a 1st Series of SIV Challenges" was published on-line in the Journal of Virology. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24574408. The print version will be available in May.
GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update
Marketwire - Wed Mar 05, 7:15AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2013 and provided the following corporate update.
GeoVax Presents at the Phacilitate Vaccine Forum 2014
Marketwire - Tue Jan 28, 12:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today that its Chief Scientific Officer, Dr. Harriet Robinson, presented information on the selection of antigens and antigen combinations for the elicitation of protective antibody responses for HIV at the Phacilitate Vaccine Forum 2014 on January 27, 2014 in Washington, DC.
GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases
Marketwire - Thu Jan 23, 9:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today the publication of the results of Phase 2a clinical testing of its JS7/MVA62B AIDS vaccine, GOVX-B11. The article, titled "Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles" was published on-line in The Journal of Infectious Diseases. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24403557.
